全球药物释放型支架市场

2030年，全球药物释放型支架市场规模将达117亿美元

全球药物释放型支架市场规模在2024年估计为83亿美元，预计到2030年将达到117亿美元，2024年至2030年的复合年增长率（CAGR）为5.8%。本报告分析的细分市场之一—无聚合物涂层，预计将以6.0%的复合年增长率成长，并在分析期结束时达到79亿美元。聚合物涂层细分市场预计在分析期内将以5.2%的复合年增长率成长。

美国市场规模估计为22亿美元，中国市场预计将以9.5%的复合年增长率成长。

美国药物释放型支架市场预计到2024年将达到22亿美元。作为世界第二大经济体，中国预计在2024年至2030年间以9.5%的复合年增长率成长，到2030年市场规模将达到26亿美元。其他值得关注的区域市场包括日本和加拿大，预计在分析期内，这两个市场的复合年增长率将分别达到1.9%和6.2%。在欧洲，德国预计将以3.1%的复合年增长率成长。

全球药物释放型支架市场－主要趋势与驱动因素概述

什么是药物释放型支架？

药物释放型支架（DES）是一种专门用于治疗冠状动脉疾病（CAD）的医疗设备，冠状动脉疾病的特征是由于斑块积聚导致冠状动脉狭窄。这些支架是涂有药物的小型网状管，药物会缓慢释放以防止再血管再阻塞，即动脉再次阻塞的情况。药物释放型支架的结构包括一个为动脉提供机械支撑的金属支架和一个控制药物随时间释放的聚合物涂层。药物可以抑制细胞增生并减轻炎症，这是预防血管再阻塞的重要因素。透过结合机械和药物治疗方法，药物洗脱支架相比仅提供结构支撑且再血管再阻塞率较高的裸金属支架（BMS）有了显着的改善。

科技进步如何改善药物释放型支架？

药物释放型支架领域取得了显着的技术进步，大大提高了其疗效和安全性。支架设计的创新，例如更细的支架樑和更柔韧的材料，改善了支架的输送性和顺应性，使其更容易通过复杂的动脉通路。可生物降解聚合物的研发，使得药物释放后能够逐渐溶解，从而减少了与永久性聚合物残留相关的长期併发症。药物製剂的进步也发挥了关键作用，新型药物能够更好地控制细胞增生和发炎。血管内超音波（IVUS）和光同调断层扫瞄（OCT）等影像技术透过提供动脉的即时高解析度影像，进一步优化了支架植入过程，确保支架的精确放置和最佳扩张。这些技术进步共同改善了患者的预后，降低了不利事件的发生率和再次手术的需求。

药物释放型支架有哪些临床应用与好处？

药物释放型支架主要用于治疗冠状动脉疾病，但也逐渐应用于其他血管疾病的治疗。药物洗脱支架也用于治疗周边动脉疾病（PAD），透过扩张腿部狭窄的动脉来改善血流，减轻疼痛和疲劳等症状。在治疗糖尿病和多支血管病变等复杂病变方面，药物洗脱支架的应用已显示出令人鼓舞的结果，并且是一种比外科手术更安全有效的治疗方法。药物洗脱支架的主要优点包括：血管再阻塞风险较低、重复重组手术需求较少、患者长期预后较佳。此外，支架植入术属于微创手术，与开胸手术相比，可缩短住院时间和加快康復速度，因此药物洗脱支架成为许多患者和医疗机构的首选方案。

推动药物释放型支架市场成长的因素是什么？

药物释放型支架市场的成长受多种因素驱动，包括技术进步、心血管疾病盛行率上升以及医疗基础设施的持续改善。生活方式的改变和人口老化导致冠状动脉疾病盛行率不断攀升，显着推动了对药物洗脱支架（DES）等有效治疗方案的需求。新一代支架技术的突破性发展，例如具有增强生物相容性和药物传输机制的新型支架的研发，正在推动市场成长。此外，病患和医疗服务提供者对微创手术的日益偏好也促使DES逐渐取代传统外科手术。监管部门的核准和有利的报销政策也在市场扩张中发挥关键作用。此外，主要产业参与者加大研发投入以及新兴市场医疗设施的扩建也创造了新的成长机会。先进影像处理技术与支架置入术的结合正在改善临床疗效，进一步巩固了DES在心血管治疗方案中的地位。这些因素，再加上人们对心臟健康的日益重视以及对心血管疾病的积极管理，正在推动药物释放型支架市场的强劲成长。

部分

涂层（无聚合物、聚合物基）；应用（冠状动脉疾病、周边动脉疾病）；最终用途（心臟中心、门诊手术中心、医院）

受访公司范例

• Abbott Laboratories
• AlviMedica
• Arterius Limited
• Biotronik SE
• Boston Scientific Corporation
• Cook Medical
• Medtronic plc
• STENTYS SA
• Terumo Corporation

人工智慧集成

我们正在利用有效的专家内容和人工智慧工具来变革市场和竞争情报。

与查询LLM或特定产业的SLM的典型做法不同，Global Industry Analysts建立了一个内容库，其中收集了来自世界各地专家的信息，包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师预测，企业的竞争地位将根据其总部所在国家、製造地以及进出口（成品和OEM）情况而改变。这种复杂多变的市场动态预计将从多个方面影响竞争对手，包括销货成本成本上升、盈利下降以及供应链重组等，以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章 市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲
• 亚太地区
• 澳洲
• 印度
• 韩国
• 亚太其他地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Drug-Eluting Stents Market to Reach US$11.7 Billion by 2030

The global market for Drug-Eluting Stents estimated at US$8.3 Billion in the year 2024, is expected to reach US$11.7 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Polymer-Free Coating, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$7.9 Billion by the end of the analysis period. Growth in the Polymer-based Coating segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 9.5% CAGR

The Drug-Eluting Stents market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Drug-Eluting Stents Market - Key Trends and Drivers Summarized

What Are Drug-Eluting Stents and How Do They Function?

Drug-eluting stents (DES) are specialized medical devices used to treat coronary artery disease (CAD), a condition characterized by the narrowing of coronary arteries due to plaque buildup. These stents are tiny mesh tubes coated with medication that is gradually released to prevent the artery from becoming blocked again, a process known as restenosis. The structure of a drug-eluting stent includes a metal scaffold to provide mechanical support to the artery, and a polymer coating that controls the release of the drug over time. The drug inhibits cell proliferation and reduces inflammation, which are critical factors in preventing restenosis. By combining mechanical and pharmacological approaches, DES offer a significant improvement over bare-metal stents (BMS), which only provide structural support and are associated with higher rates of restenosis.

How Have Technological Advancements Improved Drug-Eluting Stents?

The field of drug-eluting stents has seen remarkable technological advancements that have enhanced their efficacy and safety profiles. Innovations in stent design, such as thinner struts and more flexible materials, have improved the deliverability and conformability of the stents, allowing for easier navigation through complex arterial pathways. The development of biodegradable polymers, which gradually dissolve after delivering the drug, has reduced long-term complications associated with permanent polymer residues. Advances in drug formulations have also played a crucial role, with newer drugs offering better control over cell proliferation and inflammation. Imaging technologies, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), have further refined the deployment process by providing real-time, high-resolution images of the arteries, ensuring precise placement and optimal expansion of the stents. These technological improvements collectively contribute to better patient outcomes, reducing the incidence of adverse events and the need for repeat interventions.

What Are the Clinical Applications and Benefits of Drug-Eluting Stents?

Drug-eluting stents are primarily used in the treatment of coronary artery disease, but their applications extend to other vascular conditions as well. They are employed in the management of peripheral artery disease (PAD), where they help to open narrowed arteries in the legs, enhancing blood flow and reducing symptoms like pain and fatigue. The use of DES in treating complex lesions, such as those in patients with diabetes or multivessel disease, has shown promising results, offering a safer and more effective alternative to surgical interventions. The primary benefits of DES include a lower risk of restenosis and reduced need for repeat revascularization procedures, leading to improved long-term patient outcomes. Additionally, the minimally invasive nature of stent implantation, combined with shorter hospital stays and faster recovery times compared to open-heart surgery, makes DES a preferred option for many patients and healthcare providers.

What Drives the Growth in the Drug-Eluting Stents Market?

The growth in the drug-eluting stents market is driven by several factors, including technological advancements, increasing prevalence of cardiovascular diseases, and expanding healthcare infrastructure. The rising incidence of coronary artery disease, partly due to lifestyle changes and an aging population, is significantly boosting the demand for effective treatment options like DES. Advances in stent technology, such as the development of next-generation stents with enhanced biocompatibility and drug delivery mechanisms, are propelling market growth. Additionally, the growing preference for minimally invasive procedures among patients and healthcare providers is driving the adoption of DES over traditional surgical methods. Regulatory approvals and favorable reimbursement policies are also playing a crucial role in expanding the market reach. Furthermore, increasing investments in research and development by key industry players and the expansion of healthcare facilities in emerging markets are creating new opportunities for growth. The integration of advanced imaging technologies with stent deployment procedures is improving clinical outcomes, further strengthening the case for DES in cardiovascular treatment protocols. These factors, combined with a greater awareness of heart health and proactive management of cardiovascular conditions, are driving the robust growth of the drug-eluting stents market.

SCOPE OF STUDY:

The report analyzes the Drug-Eluting Stents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Coating (Polymer-Free, Polymer-based); Application (Coronary Artery Disease, Peripheral Artery Disease); End-Use (Cardiology Centers, Ambulatory Surgery Centers, Hospitals)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 33 Featured) -

• Abbott Laboratories
• AlviMedica
• Arterius Limited
• Biotronik SE
• Boston Scientific Corporation
• Cook Medical
• Medtronic plc
• STENTYS SA
• Terumo Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • Global Economic Update
  • Drug-Eluting Stents - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Technological Advancements in Stent Design Propel Growth in Drug-Eluting Stents Market
  • Increasing Prevalence of Cardiovascular Diseases Expands Addressable Market Opportunity
  • Innovations in Biodegradable Polymers Strengthen Business Case for Next-Generation Stents
  • Advances in Drug Formulations Enhance Efficacy and Reduce Complications
  • Growing Geriatric Population Generates Increased Demand for Cardiovascular Treatments
  • Trends in Personalized Medicine and Patient-Specific Solutions Propel Market Growth
  • Expansion of Healthcare Infrastructure in Emerging Markets Creates New Opportunities
  • Integration of Imaging Technologies and Stent Deployment Techniques Improves Outcomes
  • Focus on Long-Term Patient Outcomes and Reduced Restenosis Rates Sustains Growth
  • Adoption of Advanced Manufacturing Processes Enhances Stent Quality and Performance
  • Development of Dual Therapy Stents and Combination Products Generates New Market Segments
  • Impact of Lifestyle Changes and Risk Factors on Cardiovascular Health Drives Market Demand
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Drug-Eluting Stents Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Drug-Eluting Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Polymer-Free by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Polymer-Free by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Polymer-Free by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Polymer-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Polymer-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Polymer-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Coronary Artery Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Coronary Artery Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Coronary Artery Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Peripheral Artery Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Peripheral Artery Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Peripheral Artery Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Cardiology Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Cardiology Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Cardiology Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: USA 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: Canada 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• JAPAN
  • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Japan 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• CHINA
  • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• EUROPE
  • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Drug-Eluting Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• FRANCE
  • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 74: France Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: France Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: France 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 77: France Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• GERMANY
  • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 83: Germany Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Germany Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Germany 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Italy Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Italy 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 101: UK Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: UK Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: UK 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 104: UK Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 110: Spain Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Spain Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Spain 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 119: Russia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Russia Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Russia 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Europe Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Rest of Europe 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 138: Asia-Pacific Historic Review for Drug-Eluting Stents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 149: Australia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Australia Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Australia 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• INDIA
  • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 158: India Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: India Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: India 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 161: India Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 167: South Korea Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: South Korea Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: South Korea 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Asia-Pacific Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 185: Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 186: Latin America Historic Review for Drug-Eluting Stents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Latin America 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 197: Argentina Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Argentina Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Argentina 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 206: Brazil Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Brazil Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Brazil 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 215: Mexico Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Mexico Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Mexico 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Rest of Latin America Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Rest of Latin America 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 233: Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 234: Middle East Historic Review for Drug-Eluting Stents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Middle East 15-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 245: Iran Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Iran Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Iran 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 254: Israel Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Israel Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Israel 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Saudi Arabia Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Saudi Arabia 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 272: UAE Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: UAE Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: UAE 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Rest of Middle East Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Rest of Middle East 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030
• AFRICA
  • Drug-Eluting Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 290: Africa Recent Past, Current & Future Analysis for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Africa Historic Review for Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Africa 15-Year Perspective for Drug-Eluting Stents by Coating - Percentage Breakdown of Value Sales for Polymer-Free and Polymer-based for the Years 2015, 2025 & 2030
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Drug-Eluting Stents by Application - Coronary Artery Disease and Peripheral Artery Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Drug-Eluting Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease and Peripheral Artery Disease for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory Surgery Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Drug-Eluting Stents by End-Use - Percentage Breakdown of Value Sales for Cardiology Centers, Ambulatory Surgery Centers and Hospitals for the Years 2015, 2025 & 2030

IV. COMPETITION